treatment, said method comprising injecting an effective amount of a pharmaceutical composition into said tumor wherein said pharmaceutical composition comprises:

(a) a replication-defective adenoviral vector lacking the E1A, E1B and E3 regions of said adenovirus; and comprises a nucleic acid sequence coding for a cytokine, under the control of a promoter present in said replication-defective adenoviral vector or an exogenous promoter; and wherein said cytokine is interleukin-2 or gamma-interferon; and

(b) a pharmaceutically acceptable vehicle,

wherein said pharmaceutical composition leads to regression of said tumor in at least 40% to 50% of patients.

18. (Twice Amended) The method according to Claim 15, wherein said nucleic acid sequence coding for said cytokine is under the control of said exogenous promoter.

23. (Once Amended) The method according to Claim 18, wherein said promoter is the promoter of the IE gene of cytomegalovirus.

24. (Once Amended) A method for treating a tumor in a patient in need of such treatment, said method comprising injecting an effective amount of a pharmaceutical composition wherein said pharmaceutical composition comprises:

(a) a replication-defective adenoviral vector lacking the E1A, E1B and E3 regions of said adenovirus; and comprises a nucleic acid sequence coding for a cytokine, under the control of a promoter present in said replication-defective

adenoviral vector or an exogenous promoter; and wherein said cytokine is GM-CSF, and

(b) a pharmaceutically acceptable vehicle.

93 Cont

25. (Once Amended) The method according to Claim 24, wherein said adenoviral vector further comprises a nucleic acid sequence coding for an interleukin-2 under the control of a promoter present in said replication-defective adenoviral vector or an exogenous promoter and wherein said interleukin-2 under the control of said promoter present in said replication-defective adenoviral vector or said exogenous promoter is placed after said nucleic acid sequence coding for a cytokine in said adenoviral vector.

Please add the following new claim:

26. (New) A method for treating a tumor in a patient in need of such treatment, said method comprising injecting an effective amount of a pharmaceutical composition into said tumor wherein said pharmaceutical composition comprises:

94

(a) a replication-defective adenoviral vector lacking the E1A, E1B and E3 regions of said adenovirus; and comprises a nucleic acid sequence coding for a cytokine, under the control of a promoter present in said replication-defective adenoviral vector selected from the group of an adenovirus late promoter and an adenovirus early promoter or an exogenous promoter selected from the group of a promoter contained in the long terminal repeat of a Rous Sarcoma Virus and a promoter of an IE gene of cytomegalovirus; and wherein said cytokine is interleukin-2 or gamma-interferon; and

(b) a pharmaceutically acceptable vehicle,

94 Cont

wherein said pharmaceutical composition leads to regression and complete disappearance of said tumor in 40% to 50% of patients.